BioNTech (NASDAQ:BNTX) Price Target Lowered to $85.00 at TD Cowen

BioNTech (NASDAQ:BNTX) had its price target lowered by TD Cowen from $98.00 to $85.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a hold rating on the stock.

Other equities research analysts have also issued reports about the company. Hsbc Global Res raised BioNTech from a hold rating to a strong-buy rating in a research report on Friday, August 2nd. HC Wainwright restated a buy rating and issued a $113.00 target price on shares of BioNTech in a research note on Thursday, August 1st. Evercore ISI initiated coverage on BioNTech in a research report on Tuesday, May 14th. They set an inline rating and a $100.00 price target for the company. BMO Capital Markets dropped their price target on BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a research report on Tuesday, May 7th. Finally, HSBC raised BioNTech from a hold rating to a buy rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $109.00.

BioNTech Stock Performance

BioNTech stock traded up $0.27 during mid-day trading on Tuesday, hitting $80.80. 421,050 shares of the company’s stock traded hands, compared to its average volume of 699,074. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $125.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. The stock has a market cap of $19.21 billion, a price-to-earnings ratio of 161.60 and a beta of 0.23. The firm has a 50 day simple moving average of $86.41 and a two-hundred day simple moving average of $90.22.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the previous year, the business posted ($0.86) EPS. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis. On average, research analysts expect that BioNTech will post -2.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. GAMMA Investing LLC lifted its position in BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares during the period. CWM LLC lifted its holdings in BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after acquiring an additional 217 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in BioNTech during the fourth quarter worth $30,000. First Horizon Advisors Inc. acquired a new position in BioNTech during the fourth quarter worth $38,000. Finally, Covestor Ltd lifted its stake in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.